Abbott Receives FDA’s Emergency Use Authorization for its Point-Of-Care Test to Detect Novel COVID-19 in Five Minutes

 Abbott Receives FDA’s Emergency Use Authorization for its Point-Of-Care Test to Detect Novel COVID-19 in Five Minutes

Abbott Receives FDA’s Emergency Use Authorization for its Point-Of-Care Test to Detect Novel COVID-19 in Five Minutes

Shots:

  • Abbott has received the US FDA’s EUA for its molecular point-of-care test to detect novel COVID-19 and runs on its ID NOW platform, delivering positive results in just five mins. and negative results in 13 mins.
  • The ID NOW Covid-19 test allows HCPs to perform molecular POC testing outside the hospital in outbreak hotspots. The company anticipates scaling up manufacturing to deliver 50,000 tests/day with its expected launch in next week
  •  This marks Abbott’s second FDA’s EUA, following its first EUA for RealTime SARS-CoV-2 test, which runs on m2000 RealTime molecular system for centralized lab environments. Combining both the tests, Abbott expects to produce ~5M tests in April

Click here ­to­ read full press release/ article | Ref: Abbott | Image: Alere

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post